跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CAR-NK
首页
药物
CAR-NK
CAR-NK
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
PRIMARY NK CAR CONSTRUCTS AND METHODS
EP 4491235 A3
申请人: IMMUNITYBIO INC
优先权: 2019
CN
EP
US
WO
8 件公开
ELIMINATION OF CD19-POSITIVE LYMPHOID MALIGNANCIES BY CD19-CAR EXPRESSING NK CELLS
EP 3743512 A4
申请人: NANTKWEST INC
优先权: 2018
CN
EP
US
8 件公开
TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER
EP 3707165 A4
申请人: UNIV TEXAS
优先权: 2017
CN
EP
US
WO
6 件公开
TISSUE FACTOR-TARGETING CAR-NK AND CAR-T CELL THERAPY
EP 3687555 A4
申请人: OHIO STATE INNOVATION FOUNDATION
优先权: 2017
CN
EP
US
WO
5 件公开
LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF NK CELLS
EP 4065140 A4
申请人: UNIV TEXAS
优先权: 2019
CN
EP
US
WO
4 件公开
CHIMERIC ANTIGEN RECEPTOR (CAR) NK CELLS AND USES THEREOF
EP 4232560 A4
申请人: RES INST NATIONWIDE CHILDRENS HOSPITAL
优先权: 2020
CN
EP
US
WO
4 件公开
CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS WITH NK RECEPTOR SIGNALING DOMAIN
EP 4519306 A4
申请人: H LEE MOFFITT CANCER CENTER & RESEARCH INST INC
优先权: 2022
CN
EP
US
WO
4 件公开
CXCR3 OVEREXPRESSION IN CAR-NK CELLS PRIMES MIGRATION/HOMING INTO THE TUMOR MICROENVIRONMENT
EP 4522184 A4
申请人: DANA FARBER CANCER INST INC
优先权: 2022
CN
EP
US
WO
4 件公开
CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND NK CELLS EXPRESSING CAR CONSTRUCTS
EP 4284394 A1
申请人: CYTOCARES SHANGHAI INC
优先权: 2021
CN
EP
US
4 件公开
COMBINATIONAL IMMUNOTHERAPIES USING CAR-M, CAR-NK, CAR-EOS, AND CAR-N CELLS
EP 4511044 A4
申请人: WISCONSIN ALUMNI RES FOUND
优先权: 2022
EP
US
WO
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈